Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 2/20 | 0.74 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.74 |
| ▸ | SCD | O00767 | 3/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 7/20 | 0.61 |
| ▸ | TP53 | P04637 | 4/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.61 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL516958 | 0.88 | NPBWR1 (0.58) | NPBWR1HDAC6SCDCYP2C9CYP2C19 | |
| Hydrochloric Acid SCHEMBL23531533 | 0.87 | NPBWR1 (0.57) | NPBWR1HDAC6SCDCYP2C9CYP2C19 | |
| Ensulizole SCHEMBL38724 | 0.85 | HDAC6 (1.00) | NPBWR1HDAC6SCDCYP2C9CYP2C19 | |
| SCHEMBL14254530 | 0.85 | NPBWR1 (1.00) | NPBWR1HDAC6SCDCYP2C9CYP2C19 | |
| SCHEMBL15640487 | 0.85 | CHEK2 (0.79) | NPBWR1HDAC6SCDCYP2C9CYP2C19 | |
| Ensulizole SCHEMBL3173657 | 0.85 | NPBWR1 (0.74) | NPBWR1HDAC6SCDCYP2C9CYP2C19 | |
| Ensulizole SCHEMBL17707525 | 0.85 | NPBWR1 (0.74) | NPBWR1HDAC6SCDCYP2C9CYP2C19 | |
| Ensulizole SCHEMBL7751558 | 0.85 | HDAC6 (1.00) | NPBWR1HDAC6SCDCYP2C9CYP2C19 | |
| Ensulizole SCHEMBL1276071 | 0.84 | HDAC6 (0.97) | NPBWR1HDAC6SCDCYP2C9CYP2C19 | |
| Ensulizole SCHEMBL17351654 | 0.84 | HDAC6 (0.97) | NPBWR1HDAC6SCDCYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9923152-B2 | Organic ionic functional materials | MERCK PATENT GMBH (DE) | 2018-03-20 | — | — | US | disclosed |
| US-9923152-B2 | Organic ionic functional materials | MERCK PATENT GMBH (DE) | 2018-03-20 | — | — | US | disclosed |
| EP-2444120-B1 | Spirocyclic amiloride analogues as ENac blockers | NOVARTIS AG (CH) | 2017-09-27 | — | — | EP | disclosed |
| US-9643983-B2 | Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives | NOVARTIS AG (CH) | 2017-05-09 | — | — | US | disclosed |
| US-20160068546-A1 | TREATING DISEASES MEDIATED BY BLOCKADE OF THE EPITHELIAL SODIUM CHANNEL WITH PYRAZINE-2-CARBOXAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2016-03-10 | — | — | US | disclosed |
| US-9139586-B2 | Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives | NOVARTIS AG (CH) | 2015-09-22 | — | — | US | disclosed |
| US-20150231142-A1 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | VERTEX PHARMA (US) | 2015-08-20 | — | — | US | disclosed |
| US-20150150879-A2 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | VERTEX PHARMACEUTICALS INCORPORATED | 2015-06-04 | — | — | US | disclosed |
| US-9023889-B2 | Use of ascorbic acid derivatives for the functionalization of matrices | MERCK PATENT GMBH (DE) | 2015-05-05 | — | — | US | disclosed |
| US-9023889-B2 | Use of ascorbic acid derivatives for the functionalization of matrices | MERCK PATENT GMBH (DE) | 2015-05-05 | — | — | US | disclosed |
| EP-2049075-A2 | USE OF ASCORBIC ACID DERIVATIVES FOR THE FUNCTIONALIZATION OF MATRICES | Merck Patent GmbH (DE) | 2009-04-22 | — | — | EP | disclosed |
| US-7345090-B2 | Galenical formulation | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2008-03-18 | — | — | US | disclosed |
| US-7345090-B2 | Galenical formulation | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2008-03-18 | — | — | US | disclosed |
| US-7345090-B2 | Galenical formulation | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2008-03-18 | — | — | US | disclosed |
| WO-2008017346-A2 | USE OF ASCORBIC ACID DERIVATIVES FOR THE FUNCTIONALIZATION OF MATRICES | MERCK PATENT GMBH (DE) | 2008-02-14 | — | — | WO | disclosed |
| WO-2008017346-A2 | USE OF ASCORBIC ACID DERIVATIVES FOR THE FUNCTIONALIZATION OF MATRICES | MERCK PATENT GMBH (DE) | 2008-02-14 | — | — | WO | disclosed |
| EP-1205475-B1 | Flavonoid compounds for use against oxidative stress and UV radiation | MERCK PATENT GMBH (DE) | 2004-10-27 | — | — | EP | disclosed |
| US-20040202624-A1 | Galenical formulation | PFLUECKER FRANK (DE) | 2004-10-14 | — | — | US | disclosed |
| US-20020106338-A1 | Galenical formulation | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2002-08-08 | — | — | US | disclosed |
| EP-1205475-A1 | Flavonoid compounds for use against oxidative stress and UV radiation | MERCK PATENT GmbH (DE) | 2002-05-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160068546-A1 | TREATING DISEASES MEDIATED BY BLOCKADE OF THE EPITHELIAL SODIUM CHANNEL WITH PYRAZINE-2-CARBOXAMIDE DERIVATIVES | SCNN1B, SCNN1A, SCNN1G | NPBWR1 446/4885HDAC6 681/4885SCD 4007/4885 |
| US-20040202624-A1 | Galenical formulation | GALR1, GLA, GALR3 | NPBWR1 3421/4885HDAC6 2936/4885SCD 4074/4885 |
| US-20150231142-A1 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | CFTR, SLC26A4, ABCB11 | NPBWR1 1447/4885HDAC6 1721/4885SCD 2297/4885 |
| US-20020106338-A1 | Galenical formulation | GALR1, GLA, GALR3 | NPBWR1 3421/4885HDAC6 2936/4885SCD 4074/4885 |
| US-20150150879-A2 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | CFTR, SLC26A4, ABCB11 | NPBWR1 1447/4885HDAC6 1721/4885SCD 2297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.